Several studies have confirmed that C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) are predictive markers for treatment response and oncological outcomes in rectal cancer patients [8,9,10,11,12]. The gene discussed is CRP; the disease is rectal cancer.